Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Investment analysts at William Blair lowered their FY2024 EPS estimates for Zevra Therapeutics in a research note issued on Wednesday, November 13th. William Blair analyst S. Corwin now expects that the company will post earnings of ($2.00) per share for the year, down from their previous forecast of ($1.58). William Blair currently has a "Strong-Buy" rating on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.92) per share. William Blair also issued estimates for Zevra Therapeutics' Q4 2024 earnings at ($0.42) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.70) EPS.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $3.70 million for the quarter, compared to analysts' expectations of $5.04 million. During the same period in the previous year, the firm earned ($0.40) earnings per share.
ZVRA has been the subject of several other reports. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Monday, September 30th. Canaccord Genuity Group cut their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday. Guggenheim initiated coverage on shares of Zevra Therapeutics in a research report on Monday, October 7th. They issued a "buy" rating and a $20.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zevra Therapeutics in a research report on Friday, October 11th. Finally, JMP Securities initiated coverage on shares of Zevra Therapeutics in a research report on Tuesday, September 24th. They issued an "outperform" rating and a $17.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $21.00.
Check Out Our Latest Stock Analysis on ZVRA
Zevra Therapeutics Stock Performance
NASDAQ ZVRA traded down $0.02 during trading hours on Monday, hitting $8.60. 695,100 shares of the company's stock traded hands, compared to its average volume of 549,014. The business's fifty day moving average price is $8.03 and its two-hundred day moving average price is $6.51. The company has a current ratio of 2.88, a quick ratio of 2.00 and a debt-to-equity ratio of 0.84. The firm has a market capitalization of $452.53 million, a P/E ratio of -4.28 and a beta of 1.93. Zevra Therapeutics has a 52 week low of $4.20 and a 52 week high of $9.21.
Hedge Funds Weigh In On Zevra Therapeutics
Several hedge funds have recently modified their holdings of ZVRA. International Assets Investment Management LLC lifted its holdings in shares of Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock worth $48,000 after buying an additional 5,940 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in shares of Zevra Therapeutics in the first quarter worth $64,000. The Manufacturers Life Insurance Company raised its stake in Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company's stock valued at $91,000 after purchasing an additional 2,452 shares in the last quarter. Hunter Associates Investment Management LLC purchased a new stake in Zevra Therapeutics during the third quarter valued at $92,000. Finally, XTX Topco Ltd purchased a new stake in Zevra Therapeutics during the third quarter valued at $94,000. Hedge funds and other institutional investors own 35.03% of the company's stock.
About Zevra Therapeutics
(
Get Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
Further Reading
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
